Sabatolimab (MBG453), a humanized IgG4 antibody targeting TIM-3, was tested in a phase Ib dose-escalation study in combination with HMA and was not only tolerated in patients with AML or MD but also showed encouraging anti-leukemic activity (NCT03066648) [24]. Here, HAVCR2 is linked to acute myeloid leukemia.